within Pharmacolibrary.Drugs.ATC.A;

model A16AB14
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.1666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0019,
    k12             = 1.1,
    k21             = 1.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AB14</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme replacement therapy indicated for the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder causing the accumulation of cholesteryl esters and triglycerides. It is approved for use in both pediatric and adult patients with LAL-D.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult and pediatric (≥8 years) patients with LAL-D receiving intravenous sebelipase alfa at a dose of 1 mg/kg; values are geometric mean population PK model parameters from the published study.</p><h4>References</h4><ol><li><p>Shirley, M (2015). Sebelipase alfa: first global approval. <i>Drugs</i> 75(16) 1935–1940. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0479-6\">10.1007/s40265-015-0479-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26452566/\">https://pubmed.ncbi.nlm.nih.gov/26452566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AB14;
